Jpmorgan Chase & CO Cytosorbents Corp Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Cytosorbents Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 372 shares of CTSO stock, worth $338. This represents 0.0% of its overall portfolio holdings.
Number of Shares
372
Previous 372
-0.0%
Holding current value
$338
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CTSO
# of Institutions
53Shares Held
17.8MCall Options Held
0Put Options Held
0-
Avenir Corp Washington, DC3.17MShares$2.89 Million0.27% of portfolio
-
Granahan Investment Management, LLC Waltham, MA3.04MShares$2.77 Million0.1% of portfolio
-
Skylands Capital, LLC2.88MShares$2.62 Million0.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$1.77 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY1.91MShares$1.74 Million0.0% of portfolio
About Cytosorbents Corp
- Ticker CTSO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 43,577,400
- Market Cap $39.7M
- Description
- Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...